
EMA Reflects on Coated Nanomedicines
EMA publishes reflection paper on issues regarding the parenteral administration of coated nanomedicines.
The European Medicines Agency (EMA) has published a
The reflection paper is one in a series of four guidance documents discussing nanomedicines. EMA’s Committee for Medicinal Products for Human Use began developing guidance on the development of new nanomedicines and nanosimilars in 2011.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.